Avant Diagnostics, Inc. (AVDX) Offers A New Approa
Post# of 104
Posted On: 11/06/2015 5:27:41 PM
Avant Diagnostics, Inc. (AVDX) Offers A New Approach To Diagnosing A Deadly Cancer
Avant Diagnostics, a medical technology company focused on bringing to market cutting-edge diagnostic tests based upon the completion of the human genome sequencing project, has developed a sophisticated and much-needed screening test for diagnosing ovarian cancer. OvaDx is the market’s first large-panel biomarker screening test for ovarian cancer.
Discoveries in genetic research offer far-reaching opportunities for impacting both the diagnosis and treatment of serious disease. It centers on identifying variations in specific genes in the genome, variations that define individual characteristics, including disease states or a statistical propensity for disease. Diagnostic tests that detect diseases early in their progression will provide options for earlier treatments to improve the quality of life and outcome by delaying or preventing disease progression or even death. Medical providers will enjoy major cost savings by avoiding costly late stage disease treatments.
The American Cancer Society estimated diagnosis in 2013 of about 22,240 new cases of ovarian cancer, with perhaps 15,500 ovarian cancer deaths in the U.S., making ovarian cancer the fifth leading cause of cancer death among U.S. women. Other cancers have shown a marked reduction in mortality due to the availability of early detection tests and improved treatment, but this has not been the case with ovarian cancer, which has been called “the silent killer”. Early stage disease symptoms are often ignored, and current tests can lead to false diagnosis and unnecessary treatment. One study found that, on average, for every one case of ovarian cancer detected, 33 women had surgery for a false positive.
The Avant Diagnostics approach is based upon 10 years of genetic and physiological research, focused on exploiting the human immune system for early detection. The result, OvaDx, offers a large panel of refined markers for high sensitivity. OvaDx markers and kits are proprietary, with a patented manufacturing technology, and a worldwide exclusive license, and the company is progressing toward FDA 510(k) clearance for OvaDx.
For more information on the company, visit www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Avant Diagnostics, a medical technology company focused on bringing to market cutting-edge diagnostic tests based upon the completion of the human genome sequencing project, has developed a sophisticated and much-needed screening test for diagnosing ovarian cancer. OvaDx is the market’s first large-panel biomarker screening test for ovarian cancer.
Discoveries in genetic research offer far-reaching opportunities for impacting both the diagnosis and treatment of serious disease. It centers on identifying variations in specific genes in the genome, variations that define individual characteristics, including disease states or a statistical propensity for disease. Diagnostic tests that detect diseases early in their progression will provide options for earlier treatments to improve the quality of life and outcome by delaying or preventing disease progression or even death. Medical providers will enjoy major cost savings by avoiding costly late stage disease treatments.
The American Cancer Society estimated diagnosis in 2013 of about 22,240 new cases of ovarian cancer, with perhaps 15,500 ovarian cancer deaths in the U.S., making ovarian cancer the fifth leading cause of cancer death among U.S. women. Other cancers have shown a marked reduction in mortality due to the availability of early detection tests and improved treatment, but this has not been the case with ovarian cancer, which has been called “the silent killer”. Early stage disease symptoms are often ignored, and current tests can lead to false diagnosis and unnecessary treatment. One study found that, on average, for every one case of ovarian cancer detected, 33 women had surgery for a false positive.
The Avant Diagnostics approach is based upon 10 years of genetic and physiological research, focused on exploiting the human immune system for early detection. The result, OvaDx, offers a large panel of refined markers for high sensitivity. OvaDx markers and kits are proprietary, with a patented manufacturing technology, and a worldwide exclusive license, and the company is progressing toward FDA 510(k) clearance for OvaDx.
For more information on the company, visit www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)